
    
      The primary endpoint of the trial is the change in colonic permeability as a global
      assessment of vitamin D3 effects throughout the colon in patients with Ulcerative Colitis.
      Secondary endpoints will be changes in colonic tight junction protein expression, and their
      relationship to serum vitamin D level, VDR expression, inflammatory cytokines, and histologic
      inflammation
    
  